SSRI and SNRI Anti-depressants

**Pristiq™, Viibryd®, Trintellix™, Fetzima™, Khedezla**

**Step Therapy Guidelines**

**DESCRIPTION:** SSRIs are antidepressants with selective inhibitory effects on presynaptic serotonin reuptake and only very weak effects on norepinephrine and dopamine neuronal uptake. SNRIs are antidepressants potent inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.

**INDICATION(S):**
- Treatment of major depression
- Treatment of general anxiety disorder
- Treatment of seasonal affective disorder
- Treatment of post-traumatic stress disorder
- Treatment of obsessive compulsive disorder
- Treatment of premenstrual dysphoric disorder
- Treatment of social anxiety disorder

**REASONS FOR Step Therapy:**
- ☒ Cost
- ☐ Potential for misuse
- ☐ Toxicity

**CRITERIA for APPROVAL:**
First Patient has failed a 30 day trial of one of the follow: Fluoxetine, Paroxetine, Escitalopram, Venlafaxine, Citalopram, or Sertraline prior to a prior to a Non Preferred medication-Viibryd, Pristiq, Trintellix™, Khedezla and Fetzima™

**REASON for DENIAL of BENEFIT:**
- Patient does not meet above criteria or has hypertension with no monitoring plan
- Patient currently taking a Monoamine Oxidase Inhibitor
- Patient has existing Hypertension, without treatment plan
- Patient is breastfeeding

**BENEFIT APPROVAL:**
- Approval for three years

**References:**